All members have the option of attending our various HTC-centric events which include:
Date: Thursday, June 26th, 2025
Time: 1:00pm – 2:00pm ET
WEBINAR TITLE:
Washington Update
SESSION OBJECTIVE:
Come to hear the latest on actions in Washington that could impact your HTC and your patients – from 340B reform and federal funding for hemophilia programs, to Congress’ “One Big Beautiful Bill” and how it could lead to people with bleeding disorders losing their Medicaid or ACA health coverage. We’ll answer your questions and give you tools to advocate for your center and patients.
INTENDED AUDIENCE:
All HTC staff
SPEAKERS:
Johanna Gray serves the Hemophilia Alliance as a federal policy advocacy consultant. She has more than a decade of experience in health policy and government relations, working with clients to develop and implement successful advocacy strategies involving Congress and federal public health agencies. Johanna’s clients include patient advocacy groups, physician specialty societies, and associations of specialized treatment centers.
Johanna’s expertise in health policy ranges from the broadly applicable private insurance market reforms included in the Affordable Care Act (ACA) to the specifics of Medicare reimbursement for particular physician services. During the ACA negotiations, Johanna led a coalition of seventy patient advocacy groups and other supporters, which successfully advocated for the elimination of lifetime limits on private health insurance in the law.
Having began her career as an intern for then-Senator Barack Obama, Johanna held several policy analysis and advocacy positions before joining CRD. Johanna received a Master of Public Administration and Certificate in Health Services Management and Policy from the Maxwell School at Syracuse University and a B.A. in Public Policy Studies with honors from the University of Chicago.
Miriam Goldstein joined the Artemis Policy Group as a Senior Policy Advisor in August 2024 after more than seven years at Hemophilia Federation of America. Miriam focuses on federal and state policies impacting patient access to coverage, access to care, and affordability. Over the course of her legislative and regulatory work, Miriam has developed expertise in the Affordable Care Act and insurance reform, Medicaid eligibility and program requirements; and other keystones of the health policy landscape.
Before her time at HFA, Miriam worked as an attorney in private practice and with the US Securities and Exchange Commission. Miriam earned her J.D. degree from the University of Pennsylvania and her B.A. in history from Yale. She is admitted to practice law in D.C. Miriam lives in Arlington, Virginia, and in her free time can often be found cycling on local bike trails with her husband Dave.
Dean M. Hindenlang has served the nonprofit and government sectors for almost 30 years, focusing on strategic planning, administrative oversight and governance, and coalition-building through an equity-based lens. As Director of Public Policy and Strategic Initiatives with Cascade Hemophilia Consortium, his work focuses on coalition-building while helping ensure that individuals needing assistance are advocated for in community and government-based capacities. He is a proven leader in assisting members of marginalized and underserved communities.
Mr. Hindenlang holds a Ph.D. in Public Policy and Administration, completing his doctoral dissertation on equity in community-based programming. He has a Master of Public Administration, a Master of Science in Marketing and Communication, a Master of Healthcare Administration, and a bachelor’s degree in English. Additionally, he serves as an adjunct professor, doctoral faculty methodologist, and subject matter expert at Franklin University. He also offers undergraduate instruction on social justice and cultural awareness at Southern New Hampshire University.
As the Director of Public Policy and Strategic Initiatives, Dean serves Cascade HC by engaging local and state authorities, as well as elected officials, on matters of public policy actions, projects, and patient education and advocacy.
